Placebo to MK-8527

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

HIVHIV Pre-Exposure ProphylaxisHIV Pre-exposure ProphylaxisHuman Immunodeficiency Virus (HIV)

Phase 2

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

CompletedNCT06045507

Merck Sharp & Dohme LLCHIV, HIV Pre-exposure Prophylaxis

Start: 2023-11-08End: 2025-02-12Updated: 2026-01-07

Phase 3

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

RecruitingNCT07044297

Merck Sharp & Dohme LLCHIV Pre-Exposure Prophylaxis, Human Immunodeficiency Virus (HIV)

Start: 2025-07-31End: 2027-07-22Target: 4390Updated: 2026-03-30